Verition Fund Management
MYGN icon

Verition Fund Management’s Myriad Genetics MYGN Stock Holding History

Verition Fund Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-129,521
Closed -$936K – 3792
2025
Q3 		$936K Buy
129,521
+101,857
+368% +$605K ﹤0.01% 2583
2025
Q2 		$147K Sell
27,664
-20,278
-42% -$120K ﹤0.01% 3433
2025
Q1 		$425K Buy
47,942
+14,949
+45% +$180K ﹤0.01% 2681
2024
Q4 		$452K Sell
32,993
-55,910
-63% -$1.03M ﹤0.01% 2544
2024
Q3 		$2.44M Buy
88,903
+80,411
+947% +$2.18M 0.01% 1301
2024
Q2 		$208K Buy
+8,492
New +$186K ﹤0.01% 2572
2017
Q2 		– Sell
-10,662
Closed -$205K – 1167
2017
Q1 		$205K Sell
10,662
-11,774
-52% -$209K 0.02% 1034
2016
Q4 		$374K Buy
+22,436
New +$406K 0.03% 701
2016
Q3 		– Sell
-8,931
Closed -$273K – 1245
2016
Q2 		$273K Buy
+8,931
New +$310K 0.03% 634

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Verition Fund Management's MYGN Position: Q4 2025 in Review

Verition Fund Management sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 129,521 shares — an estimated $936K sold.

Verition Fund Management first reported a position in MYGN in Q2 2016 and held it in 9 quarters. The position peaked at $2.44M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Verition Fund Management reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 129,521 Myriad Genetics shares in Q4 2025, an estimated $936K.
  • Verition Fund Management first reported a position in Myriad Genetics in Q2 2016 and held it in 9 quarters.
  • Verition Fund Management's Myriad Genetics position peaked at $2.44M in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.